

1 **Factors associated with adverse outcomes among patients hospitalized at a COVID-19**  
2 **treatment center run by Médecins sans Frontières in Herat, Afghanistan**

3  
4 **Short title: Factors associated with adverse outcomes among COVID-19 patients in**  
5 **Afghanistan**

6  
7  
8 *Ana Klein<sup>1</sup>, Mathieu Bastard<sup>1</sup>, Hamayoun Hemat<sup>2</sup>, Saschveen Singh<sup>3</sup>, Bruno Muniz<sup>3</sup>, Guyguy*  
9 *Manangama<sup>3</sup>, Amber Alayyan<sup>3</sup>, Abdul Hakim Tamanna<sup>4</sup>, Bashir Barakzaie<sup>4</sup>, Nargis Popal<sup>4</sup>, Mohammad*  
10 *Azeem Zmarial Kakar<sup>5</sup>, Elisabeth Poulet<sup>1</sup>, Flavio Finger<sup>1</sup>*

11  
12 <sup>1</sup>Epicentre, Paris, France

13 <sup>2</sup>Médecins sans Frontières, Kabul, Afghanistan

14 <sup>3</sup>Médecins sans Frontières, Paris, France

15 <sup>4</sup>Ministry of Public Health, Herat, Afghanistan

16 <sup>5</sup>Ministry of Public Health, Kabul, Afghanistan

17

18

19

20

21

22 **Corresponding Author:**

23 Ana Klein MD, Epicentre, 14-34 Avenue Jean Jaurès, 75019 Paris, France; [ana.katha.klein@gmail.com](mailto:ana.katha.klein@gmail.com)

24

25 **Abstract**

26 **Background**

27 Though many studies on COVID have been published to date, data on COVID-19 epidemiology,  
28 symptoms, risk factors and severity in low- and middle-income countries (LMICS), such as  
29 Afghanistan are sparse.

30 **Objective**

31 To describe clinical characteristics, severity, and outcomes of patients hospitalized in the MSF  
32 COVID-19 treatment center (CTC) in Herat, Afghanistan and to assess risk factors associated with  
33 severe outcomes.

34 **Methods**

35 1113 patients were included in this observational study between June 2020 and April 2022.  
36 Descriptive analysis was performed on clinical characteristics, complications, and outcomes of  
37 patients. Univariate description by Cox regression to identify risk factors for an adverse outcome  
38 was performed. Adverse outcome was defined as death or transfer to a level 3 intensive care  
39 located at another health facility. Finally, factors identified were included in a multivariate Cox  
40 survival analysis.

41 **Results**

42 A total of 165 patients (14.8%) suffered from a severe disease course, with a median time of 6  
43 days (interquartile range: 2-11 days) from admission to adverse outcome. In our multivariate  
44 model, we identified male gender, age over 50, high O<sub>2</sub> flow administered during admission,  
45 lymphopenia, anemia and O<sub>2</sub> saturation  $\leq 93\%$  during the first three days of admission as  
46 predictors for a severe disease course ( $p < 0.05$ ).

47 **Conclusion**

48 Our analysis concluded in a relatively low rate of adverse outcomes of 14.8%. This is possibly  
49 related to the fact, that the resources at an MSF-led facility are higher, in terms of human resources  
50 as well as supply of drugs and biomedical equipment, including oxygen therapy devices, compared  
51 to local hospitals. Predictors for severe disease outcomes were found to be comparable to other  
52 settings.

## 53 List of abbreviations

ARDS	Acute respiratory distress syndrome
BP	Blood pressure
CI	Confidence interval
COVID (-19)	Coronavirus disease
CRP	C-reactive protein
CTC	COVID-19 treatment center
HIV	Human immunodeficiency virus
HR	Hazard ratio
ICU	Intensive care unit
IQR	Interquartile range
LMIC	Low- to middle-income country
MSF	Médecins Sans Frontières
PCR	Polymerase chain reaction
REDCap	Research Electronic Data Capture
WBC	White blood cell
WHO	World Health Organization

## 55 **Introduction**

### 56 *Covid-19*

57 Since the initial outbreak of the coronavirus disease (COVID-19) in December 2019 in Wuhan, China,  
58 SARS-CoV-2 has spread across the globe affecting millions of people. As of July 2022, the number of past  
59 and current infections reported to the WHO rose to more than 550 million cases with more than six million  
60 cumulative deaths.<sup>1</sup>

61 Though most cases are mild and do not require hospitalization, approximately 14% of patients recorded in  
62 the literature experience a severe and 5% a critical course<sup>2, 3</sup>. This, however, highly depends on the age  
63 structure and prevalence of underlying risk factors within the population. In populations with a younger age  
64 structure, such as Afghanistan, the proportion of recorded severe and critical disease cases tend to be lower.<sup>4</sup>  
65 Common complications described in studies of patients with a severe disease course include acute  
66 respiratory distress syndrome (ARDS) or cardio- and cerebrovascular complications, due to the pro-  
67 coagulant nature of the disease.<sup>5-9</sup>

68 After admission to hospital, published mortality rates range widely between 2% and 60%, depending on  
69 various factors such as the type of care facility (e.g., equipped for critical care or not), hospital equipment  
70 and number and qualification of staff.<sup>10-15</sup> Multiple meta-analyses have estimated the in-hospital mortality  
71 to be around 17% (95% CIs ranging from 12.7% to 22.7%)<sup>16, 17</sup>

72 Many studies have researched predictors for in-hospital mortality. Identified factors have included: higher  
73 age, male gender, low oxygen saturation at admission, tachypnea and various laboratory determinants such  
74 as lymphopenia, low hemoglobin levels, elevated c-reactive protein (CRP), lactate dehydrogenase (LDH)  
75 and urea, hyponatremia, hyperkalemia and abnormal coagulation parameters.<sup>11, 18-25</sup>

76

77

78 *Rationale*

79 From China the virus spread first to high-income countries, followed shortly by low- and middle-income  
80 countries (LMIC). Due to the weaker socioeconomic status, fragile health-systems and infrastructure of  
81 these countries, the impact of COVID-19 on the population and health systems raised concerns. The  
82 situation in LMICs may lead to a different profile of disease severity and finally potentially higher risk of  
83 death in individuals with risk factors for severe disease, due to a lack of medical infrastructure, skilled staff,  
84 intensive care capacity and biomedical equipment or otherwise well-functioning services that become  
85 quickly overwhelmed.<sup>14</sup> Furthermore, while LMICs tend to have a younger age structure,<sup>26, 27</sup> which has  
86 been identified as a possible protective factor,<sup>28</sup> non-communicable diseases such as diabetes and chronic  
87 vascular disease are on the rise in many LMICs and are often poorly controlled, or undiagnosed and  
88 consecutively left untreated, predisposing to higher risk of complications.<sup>29-32</sup>

89 From both a public health and a clinical perspective, it is therefore vital to determine key predictors for  
90 unfavorable disease outcomes, in order to better estimate the likely burden on the health system and the  
91 resources required for future waves of COVID-19, to aid physicians in triaging patients appropriately and  
92 allocating valuable resources such as oxygen therapy to those in greatest need.

93 The first case of COVID in Afghanistan was detected in February 2020 in Herat.<sup>33</sup> Nationally, as of July  
94 2022, approximately 180,000 confirmed cases and 7700 deaths from COVID have been reported to the  
95 WHO. It is, however, estimated that the actual numbers are much higher due to persistent limitations in  
96 capacity of laboratory and surveillance infrastructure.<sup>1, 34</sup> The first wave of disease is hypothesized as being  
97 linked to the large influx of Afghan refugees returning from neighboring Iran, which was heavily affected  
98 in the early stages of the pandemic.<sup>35, 36</sup> As of July 2022, Afghanistan has been hit by four waves, the first  
99 spanning from April to June 2020, the second from October 2020 to December 2020, the third from April  
100 2021 to August 2021 and the fourth and most recent wave from January to April 2022.<sup>37</sup>

101 Since the onset of the pandemic, Médecins Sans Frontières (MSF) has been working in many affected  
102 countries, with interventions ranging from basic community education and health worker trainings, to  
103 setting up mobile clinics, and COVID-19 treatment centers (CTC) of varying capacity and levels of care.  
104 In Herat, Afghanistan, MSF set up a CTC which opened in July 2020. Here, we report on the disease  
105 characteristics, severity, and outcomes among COVID-19 patients admitted to the CTC.

## 106 **Methods**

### 107 *Study design*

108 The study follows a mixed prospective and retrospective observational design. Data collection was  
109 performed between 26<sup>th</sup> of June 2020 and 14<sup>th</sup> of March 2022. The prospective component began after  
110 approval of the protocol by the institutional Review Board of Afghanistan on the 16<sup>th</sup> of August 2020. All  
111 data from before this time was collected retrospectively from clinical patient files.

### 112 *Study site*

113 Study site is the MSF CTC in Herat, Afghanistan, a major city (estimated population of 600'000)<sup>38</sup> and the  
114 regional capital of the Western Region and provincial capital of the Herat province (estimated population  
115 of 2.2M)<sup>38</sup>. The CTC was initially providing basic level 1 ICU care with the provision of standard oxygen  
116 therapy, later upgrading to level 2 ICU capacity from December 2020 with the arrival of non-invasive  
117 ventilation equipment. The CTC admitted patients corresponding to the MSF definition (and WHO's initial  
118 2020 definition) of moderate and severe COVID-19 disease, as identified at the MSF-run COVID-19 triage  
119 located at the Herat Regional Hospital, which acts as the corner stone of the COVID-19 care system in  
120 Herat. The CTC initially opened in June 2020. It was temporarily closed after first and second waves of  
121 COVID-19, to reopen at the start of the next wave. It did however remain open between wave three and  
122 four due to continuous presentation of cases meeting admission criteria, until its definitive closure in April  
123 2022. It is important to note however that the MSF triage remained open both in between and throughout  
124 successive waves, this was part of MSF's surveillance strategy and to ensure that patients presenting with

125 COVID-19 between major waves could be identified and either isolated as outpatients or referred for  
126 inpatient isolation and management. The MSF CTC did not initially admit patients presenting in a critical  
127 state since there was no possibility of high flow non-invasive ventilation or intubation. Instead, critical  
128 patients were sent to Shaidayee hospital, a CTC run by a local NGO on behalf of the MoH. From Dec 2020  
129 with the arrival of High Flow Nasal Oxygen therapy (HFNO), MSF teams kept patients meeting MSF  
130 criteria for critical disease (i.e. those requiring high flow non-invasive ventilation could be managed if  
131 deemed appropriate by MSF clinicians). Other treatments included antibiotics, antipyretics, steroids, and  
132 anticoagulants and treatments for any co-morbidities according to MSF protocol.

133 PCR (polymerase chain reaction) testing was not done for all patients due to lack of laboratory capacity in  
134 Herat. The national policy, which recommends testing of suspected cases over 50, severe cases (i.e., those  
135 requiring oxygen and hence admission), health care workers and pregnant women with symptoms, was  
136 applied to prioritize testing. Antigenic Rapid Diagnostic Tests (RDTs) were used to complement when  
137 available.

#### 138 *Study population*

139 The study population consists of all clinically suspected or lab-confirmed COVID-19 patients admitted to  
140 the CTC who have consented to their data being used or met the exemption criteria (see Ethical  
141 considerations).

142 Inclusion criteria were designed as: Clinically suspected or lab-confirmed COVID-19, and consent to  
143 participate in the study, and with outcome either discharge to home, transfer to ICU or death.

#### 144 *Data collection*

145 Routinely collected data included the patients' medical history, clinical examination including vital signs  
146 at admission, lab results, including COVID-19 RT-PCR done at the Herat Regional Reference Laboratory,  
147 antigen RDTs, baseline blood test results and other clinically indicated tests upon the physician's discretion  
148 where available (e.g., serological testing for human immunodeficiency virus (HIV), X-ray, or pregnancy  
149 tests). Patients were continuously monitored, and their vital signs documented throughout the day. In



150 general, two daily values of vital signs were entered into the database (approximately at 8am and 6pm).

151 Data on treatments, outcomes and complications were also collected. More information can be found in the

152 supplementary table.

153 Study data were collected from patient files as documented by physicians and nurses during admission, stay

154 and discharge. Study data were collected and managed using REDCap electronic data capture tools hosted

155 at Epicentre, Paris.<sup>39, 40</sup>. All identifying information was removed, so that only deidentified data with a

156 patient identification number is used for the statistical analysis.

157 Data was collected throughout four waves of the pandemic, whenever the CTC was admitting patients:

158 • First Wave: admissions from the 26<sup>th</sup> of June to the 20<sup>th</sup> of September 2020,

159 • Second Wave: admissions from the 1<sup>st</sup> of December 2020 to the 1<sup>st</sup> of March 2021

160 • Third Wave: admissions from the 8<sup>th</sup> of June 2021 to the 25<sup>th</sup> of October 2021

161 • Fourth Wave: admissions from the 26<sup>th</sup> of October 2021 to the 14<sup>th</sup> of March 2022

162 *Descriptive analysis*

163 Continuous variables were described by median and interquartile range (IQR), categorical data by counts,

164 proportions and 95% confidence intervals (95% CI). Descriptive analysis was performed on

165 sociodemographic data, clinical characteristics, complications, and outcomes.

166 *Severity at admission*

167 Severity was assessed by the physicians in charge upon admission and based on the MSF COVID-19

168 guidelines (Table 1).

169

170

171

172

173 **Table 1:** Disease severity at admission based on the MSF COVID guidelines  
 174

<b>Mild disease</b>	<b>Moderate disease</b>	<b>Severe disease</b>	<b>Critical disease</b>
Respiratory rate <24/min	Respiratory rate 24-30/min	Fever or suspected respiratory infection <b>AND</b> one of the following:	Severe COVID <b>AND</b> >10 litres of oxygen at admission, OR ARDS/sepsis/shock OR Intubation
O2 saturation ≥94 % on room air after 3 minutes of moderate exercise	O2 saturation ≥94 % on room air after 3 minutes of moderate exercise	<ul style="list-style-type: none"> <li>• Respiratory rate &gt;30/min</li> <li>• Severe respiratory distress</li> <li>• O2 saturation ≤93% on room air</li> <li>• GCS &lt;15</li> </ul>	
No signs of pneumonia	No signs of severe pneumonia		
Normal pulmonary exam	Non-complicated pneumonia and mild bronchospasm in pulmonary exam	Severe pneumonia or sepsis	
		Complicated pneumonia or moderate to severe bronchospasm in pulmonary exam	

175

176 *Adverse outcomes*

177 Since the CTC wasn't equipped for level 3 ICU (intubation and mechanical ventilation), until dec 2020  
 178 patients in critical states were generally referred to Shaidayee hospital, which had a level 3 ICU and was  
 179 run by a local NGO on behalf of the MoH. From Dec 2020 with arrival of HFNO, MSF teams had capacity  
 180 to admit patients requiring higher flow of O2 and thus reducing the need to refer. The outcomes of patients  
 181 referred to Shaidayee could unfortunately not be determined on an individual basis, but anecdotal evidence  
 182 states that the mortality among the patients referred was high.

183 Thus, for this study, adverse outcome was defined as death or transfer to the level 3 ICU at Shaidayee  
184 hospital, while a mild disease course was defined as discharge to home or referral to a convalescence unit.

#### 185 *Cox regression*

186 In a second step uni- and multivariable Cox regression with time dependent co-variables was performed to  
187 identify risk factors for adverse outcome, with death or transfer to a level 3 ICU vs discharge to home as  
188 the dependent variable. Independent covariates included basic patient demographics, vaccination status,  
189 COVID-19 test result, clinical information at admission, laboratory parameters and vital signs. Vital signs  
190 were included as time dependent co-variables. To adequately address our main research question, we only  
191 included data from the first three days after admission. Time at risk was calculated as the time between  
192 admission and outcome. To increase clinical relevance, we decided to categorize our variables and set  
193 clinically relevant cutoffs, which were as follows: Age > 50 years, hemoglobin <12 g/dl, lymphocytes <500  
194  $10^3/\mu\text{l}$  and O<sub>2</sub> saturation  $\leq 93\%$ .

195 As lymphocytes were collected as % of WBC, we transformed this variable into absolute values by  
196 multiplying with the median number of WBC over all measurements. Due to discrepancies within the  
197 database and a too high proportion of missing values, underlying comorbidities were not included in the  
198 analysis.

199 After performing the univariate analysis, we selected variables based on their statistical significance (p-  
200 value <0.1), their clinical relevance and completeness of data in descending order of importance to be  
201 included in our multivariate model. Adjusted hazard ratios were expressed with 95% confidence intervals  
202 (CI) and an alpha level of 5%. All analyses were performed using R 4.1.2 (The R Foundation for Statistical  
203 Computing, Vienna, Austria).

#### 204 *Ethical considerations*

205 The research described here has been conducted according to the principles expressed in the Declaration of  
206 Helsinki. This study was approved by the Institutional Review Board of the Afghan National Public Health

207 Institute (Protocol A.0820.0214, 12 August 2020) and by the MSF Ethical Review board (Protocol 2043a,  
208 20 August 2020). All patients included in the study either verbally consented for their deidentified data to  
209 be used or met the exemption criteria approved by the Ethical Review Boards (patient discharged before  
210 the study started and thus included retrospectively OR patient deceased before the verbal consent could be  
211 taken). Verbal consent was warranted due to widespread illiteracy and since the study presents minimal risk  
212 to participants and does not include any procedure for which written consent is normally required.

## 213 **Results**

### 214 *Inclusions*

215 During the entire period of operation, a total number of 1428 patients were admitted to the CTC. After  
216 exclusion of 315 patients who did not meet the inclusion criteria, a total of 1113 clinically suspected or  
217 serologically confirmed COVID-19 patients were included in the study. Of these, 99 patients were included  
218 in the retrospective part (discharge before the study start on 16.08.2020) and thus exempt from individual  
219 consent.

### 220 *Weekly admissions and outcomes*

221 Figure 1 gives an overview of weekly admissions throughout the periods when the CTC was open, stratified  
222 by outcome. An average of just below 17 patients were admitted per week. During wave 1, 169 patients  
223 were included, during wave 2, 3 and 4, 278, 381 and 285 patients were admitted respectively.

224 **Figure 1:** Weekly admissions stratified by outcome.

225 Number of patients admitted to the CTC per week stratified by outcome. As can be seen in the graph, the  
226 CTC remained open between waded 3 and 4.

227

### 228 *Demographic and clinical characteristics*

229 The median age of all patients was 60 years, with an IQR of 47 to 70 years and only slight variations  
230 between waves (Table 2). Of the 1109 patients for whom gender is known, 591 (53%) were female. Only  
231 during wave 3 the proportion of males was higher (59%).

232 A total of 52 patients reported to be vaccinated against COVID-19, all of whom were hospitalized during  
233 the third and fourth waves (table 1, COVID-19 vaccination started in November 2021 in Herat). The  
234 proportion of vaccinated individuals was 17% when considering only patients admitted after vaccination  
235 first became available (52 out of 300 patients in total). The most common vaccine was Johnson & Johnson  
236 (40 patients, 77% of vaccinated), followed by AstraZeneca (3, 6%) and Sinopharm (1, 2%). The latter two  
237 vaccines require two doses, our patients however reported to have received one dose only. For 8 patients,  
238 data on the type of vaccine used was not available.

239 A total of 951 patients were tested for COVID-19, of these 109 patients were tested twice. The most  
240 commonly used test was RT-PCR, however in some cases antigenic RDTs were performed, which became  
241 available during the third wave. In total, 773 patients were tested with RT-PCRs and 282 with RDTs, while  
242 the choice of test was unknown for 5 cases. Of the patients tested with RT-PCR, 355 (46%) had a negative  
243 and 418 (54%) at least one positive RT-PCR or RDT result. Comparison of all four waves shows that the  
244 highest proportion of positive tests was during wave 3 with 183 patients (81%) testing positive at least once,  
245 compared to only 81 patients (34%) during wave 2 (Table 2). Almost all patients tested with RDTs had  
246 positive results, with only 10 out of 282 patients receiving a negative test result (4%).

247 Most patients were classified as severe or critical at admission (975 patients; 91% of total cohort), compared  
248 to only 101 patients (9%) who were mild to moderate. During the first wave 46% of patients were classified  
249 as severe upon admission, while this number increased continuously up to 100% during the fourth wave,  
250 which was partially due to limited bed capacity and stricter application of admission criteria.

251 All patients received oxygen at admission. 415 (55%) received under five, 244 (32%) five to ten, and 92  
252 (12%) over ten liters of oxygen per minutes.

253 Median O<sub>2</sub> saturation was 86% (IQR: 81-90%) at admission for the total cohort. Analysis stratified by wave  
254 showed that this number decreased through waves, with a median O<sub>2</sub> saturation of 92% (IQR: 89-95%) at  
255 admission during the first and 83% (IQR: 75-88%) during the fourth wave (Table 2).

256 Basic blood laboratory analysis was performed in most patients. The most frequently performed analysis  
 257 was a complete blood count with differential test, while other parameters such as CRP was tested only upon  
 258 the physician’s discretion. If a patient received more than one blood analysis, results were averaged to  
 259 facilitate analysis (Table 2).

260

261 **Table 2:** Sociodemographic and clinical characteristics

		Total cohort	Wave			
			1	2	3	4
<b>Patient demographics</b>						
<b>Number of patients</b>						
[n]		1113	169	278	381	285
<b>Sex</b>						
[n (%)]	<i>Female</i>	591 (53)	96 (57)	166 (60)	158 (41)	171 (60)
	<i>Male</i>	518 (47)	71 (43)	110 (40)	223 (59)	114 (40)
	<i>Missing values</i>	4	2	2	0	0
<b>Age (y)</b>						
[Median (IQR)]		60 (47-70)	60 (46-70)	60 (45-70)	60 (45-68)	63 (50-70)
<b>Vaccination status</b>						
[n (%)]	<i>Vaccinated</i>	52 (17)	-	-	2 (3)	50 (21)
	<i>Non-vaccinated</i>	248 (83)	-	-	63 (97)	185 (79)
	<i>Missing values</i>	813	169	278	316	50
<b>RT-PCR result</b>						
[n (%)]	<i>Negative</i>	355 (46)	63 (40)	160 (66)	44 (19)	88 (59)
	<i>Positive</i>	418 (54)	94 (60)	81 (34)	183 (81)	60 (41)
	<i>Not tested</i>	340	12	37	154	137
<b>RDT result</b>						
[n (%)]	<i>Negative</i>	10 (4)	-	-	9 (5)	1 (1)
	<i>Positive</i>	272 (96)	-	-	184 (95)	88 (99)
	<i>Not tested</i>		169	278	188	196
<b>Characteristics at admission</b>						
<b>Days since onset</b>						
[Median (IQR)]		7 (5-10)	7 (4-10)	7 (4-10)	8 (6-10)	7 (4-10)
	<i>Missing values</i>	89	6	16	43	24
<b>Admission status</b>						
[n (%)]	<i>Mild-moderate</i>	101 (9)	86 (52)	11 (4)	4 (1)	0 (0)
	<i>Severe-critical</i>	975 (91)	79 (48)	264 (96)	350 (99)	282 (100)
	<i>Missing values</i>	37	4	3	27	3

n

[n (%)]	<i>&lt;5L/min</i>	415 (55)	24 (47)	88 (69)	166 (50)	137 (57)
	<i>5-10L/min</i>	244 (32)	18 (35)	26 (20)	127 (38)	73 (30)
	<i>&gt;10L/min</i>	92 (12)	9 (18)	14 (11)	39 (12)	30 (12)
	<i>Missing values</i>	362	118	150	49	45
<b>O2 Saturation (%)</b>						
[Median (IQR)]		86 (81-90)	92 (89-95)	89 (85-94)	85 (81-88)	83 (75-88)
	<i>Missing values</i>	62	24	8	17	13
<b>Laboratory results during stay</b>						
<b>WBC (10<sup>3</sup>/μl)</b>						
[Median (IQR)]		10 (7-14)	10 (7-13)	11 (7-15)	11 (8-15)	10 (7-14)
	<i>Missing values</i>	370	41	72	181	76
<b>Lymphocytes (% of WBC)</b>						
[Median (IQR)]		10 (7-16)	15 (10-24)	9 (6-15)	10 (7-14)	10 (7-16)
	<i>Missing values</i>	370	41	72	181	76
<b>Hemoglobin (g/dl)</b>						
[Median (IQR)]		14 (13-15)	13 (12-14)	14 (13-15)	14 (13-15)	15 (13-16)
	<i>Missing values</i>	370	41	72	181	76
<b>CRP (mg/l)</b>						
[Median (IQR)]		96 (48-192)	NA	NA	48 (48-102)	96 (48-192)
	<i>Missing values</i>	782	169	278	254	81

262 **Abbreviations:** CRP: C-reactive protein; IQR: Interquartile range; WBC: White blood cells

263 During the first wave, the three most common symptoms documented at admission were fever, shortness  
 264 of breath and cough. While cough and shortness of breath remained among the top three reported symptoms  
 265 for the following two waves, presentation with fever became continuously less frequent. The third most  
 266 frequently reported symptoms for waves 2 and 3 were chest pain and headache respectively, while muscle  
 267 and chest pain tied for the third position during the fourth wave. Abdominal and nasal symptoms were of  
 268 less importance throughout all four waves (Figure 2).

269

270 **Figure 2:** Most common symptoms of patients at admission stratified by wave

271

272

273

274 *Vital signs*

275 We analyzed the evolution of O<sub>2</sub> saturation and systolic and diastolic blood pressure over the first ten days  
276 after admission stratified by outcome (Figure 3), including a linear trend line. Overall, the median O<sub>2</sub>  
277 saturation levels of patients with a more severe outcome were lower than in those with a positive outcome.  
278 While the trend line of both groups decreases over time, the decrease is steeper in patients with an adverse  
279 outcome. Median O<sub>2</sub> saturation levels at day 2 were 94% (IQR: 92-96%) in patients with a positive outcome  
280 vs 91% (IQR: 88-94%) in patients with an adverse outcome. On days 5 and 10 saturation levels were 94 vs  
281 89 % (IQR: 91-95% and 85-93%) and 93 vs 88% (90-94% and 84-91%) respectively.

282 For the evolution of systolic and diastolic blood pressure, the difference according to outcome is less  
283 pronounced (Figure 3B and C). Regarding systolic blood pressure, patients with an adverse outcome have  
284 slightly lower blood pressure values than those with a positive outcome. While the trend line of the first  
285 group remains stable, the trend line of the latter shows a slight increase of blood pressure values over time.  
286 Regarding diastolic blood pressure, values are at an equal level in both groups. Note the important number  
287 of values far over the normal range. Also note that this descriptive analysis of vital signs suffers from right-  
288 censoring since patients who were discharged do not contribute to the averages of subsequent days.

289 **Figure 3:** Evolution of patients' vital signs over the first ten days after admission

290 A: O<sub>2</sub> Saturation over time; B: Systolic blood pressure over time; C: Diastolic blood pressure over time  
291 All graphs include median values, IQR and a linear trendline. Values for patients with a positive outcome  
292 are shown in blue, orange stands for patients with an adverse outcome.

293 **Abbreviations:** bp: blood pressure

294

295 *Complications and outcomes*

296 A total of 78 patients (7.0 %) experienced one or more complications during their hospital stay, with the  
297 largest proportion of patients experiencing complications during the first wave (18 patients; 10.7%), and  
298 the smallest during the second (8 patients; 2.9%, table 3). The three most frequent were pneumological  
299 complications such as respiratory failure, ARDS, and pneumonia (37, 21 and 19 patients or 3.3, 1.9 and  
300 1.7% of all patients respectively), followed by cardiac problems such as heart failure or shock.



301 Within the complete cohort a total of 165 patients (15%) experienced an adverse outcome, while 948  
 302 patients (85%) were discharged to home. The lowest proportion of adverse outcomes occurred in wave 2  
 303 (19 patients; 6.8%), while the highest was documented during wave 3 (89 patients; 23%, table 3). Median  
 304 time to discharge to home was 5 days (IQR: 2.1-6.1 days) for the total cohort with variations between 3  
 305 days (IQR: 2.0-6.0 days) in wave 2 and 5 days (IQR: 3.1-8.1 days) in wave 3. Median time to adverse  
 306 outcome was generally one day longer (Table 3).

307 **Table 3:** Complications and outcome

Characteristic	Total cohort	Wave				
		1	2	3	4	
<b>Complications</b>						
<b>Respiratory failure</b>						
[n (%)]	37 (3.3)	5 (3.0)	5 (1.8)	18 (4.7)	9 (3.2)	
<b>ARDS</b>						
[n (%)]	21 (1.9)	1 (0.6)	0 (0.0)	14 (3.7)	6 (2.1)	
<b>Pneumonia</b>						
[n (%)]	19 (1.7)	9 (5.3)	3 (1.1)	5 (1.3)	2 (0.7)	
<b>Heart failure</b>						
[n (%)]	13 (1.3)	3 (1.8)	2 (0.7)	6 (1.6)	2 (0.7)	
<b>Shock</b>						
[n (%)]	10 (0.9)	1 (0.6)	0 (0.0)	5 (1.3)	4 (1.4)	
<b>Other complications*</b>						
[n (%)]	21 (1.9)	3 (1.8)	2 (0.7)	5 (1.3)	11 (3.9)	
<b>Any complications**</b>						
[n (%)]	78 (7.0)	18 (10.7)	8 (2.9)	31 (8.1)	21 (7.4)	
<b>Outcome</b>						
[n (%)]						
	<i>ICU/Death</i>	165 (14.8)	15 (8.9)	19 (6.8)	89 (23.4)	42 (14.7)
	<i>Discharge</i>	948 (85.2)	154 (91.1)	259 (93.2)	292 (66.6)	243 (85.3)
<b>Days to outcome</b>						
[Median	<i>ICU/Death</i>	6	6.1	3.0	6.1	3.5
(IQR)]		(2.0-11.0)	(0.1-9.1)	(1.5-7.5)	(3.1-10.1)	(2.0-10.0)
	<i>Discharge</i>	5	3.1	3.0	5.1	4.0
		(2.1-6.1)	(2.1-4.1)	(2.0-6.0)	(3.1-8.1)	(3.0-7.0)

308 \* All complications occurring in less than 10 patients \*\* Patients may have had more than 1 complication

309 **Abbreviations:** ARDS: Acute respiratory distress syndrome; IQR: Interquartile range

310

311

312

313 *Multivariable survival analysis*

314 To identify possible factors associated with a severe disease course, we performed uni- and multivariate  
315 survival analysis using Cox proportional hazard models.

316 In our univariate model male gender, a severe to critical status at admission, higher O<sub>2</sub> flow at admission,  
317 an increase in white blood cells, anemia, O<sub>2</sub> saturation < 94% and higher systolic and diastolic blood  
318 pressure were significantly associated with an increased risk of adverse outcome (p<0.05).

319 Our multivariate model included gender, age, wave, O<sub>2</sub> flow at admission, lymphocytes, hemoglobin and  
320 O<sub>2</sub> saturation over the first three days. Apart from epidemic wave and lymphopenia, all variables showed  
321 a significant association with the outcome (p<0.05).

322 Male gender and age over 50 both were associated with an approximately twofold increase in risk of an  
323 adverse outcome with a HR of 1.92 (95% CI: 1.14-3.24; p-value: 0.015) and 2.28 (95% CI: 1.14-4.56; p-  
324 value: 0.020) respectively. A higher O<sub>2</sub> flow at admission was also associated with an increase in risk of an  
325 adverse outcome, with a HR of 2.52 and 5.19 for an oxygen flow between 5 and 10 liters and over 10 liters  
326 respectively (95% CIs: 1.32-4.79 and 2.62-10.29; p-values: 0.005 and <0.001 respectively). Furthermore,  
327 anemia with a hemoglobin level of less than 12 g/dl was associated with a statistically significant increase  
328 in risk (p<0.05) of an adverse outcome, while lymphopenia with <500 cells x 10<sup>3</sup>/μl showed a trend towards  
329 an association with the outcome but was not significant with a p-value of 0.059 (Table 4). Regarding our  
330 time-dependent variable, an O<sub>2</sub> saturation of under 94% within the first three days was associated with a  
331 twofold increase in risk of an adverse event, with an HR of 2.08 (95% CI: 1.14-3.81).

332

333

334

335

336 **Table 4:** Univariate and multivariate Cox Proportional-Hazards Model with time-dependent covariates

Variable	Unit	Univariate analysis		Multivariate analysis	
		HR (95% CI)	p-value	HR (95% CI)	p-value
<b>Patient characteristics</b>					
Gender	<i>Female</i>	Ref	Ref	Ref	Ref
	<i>Male</i>	1.59 (1.16-2.16)	0.004	1.92 (1.14-3.24)	0.015
Age	$\leq 50y$	Ref	Ref	Ref	Ref
	$> 50y$	1.33 (0.94-1.87)	0.111	2.28 (1.14-4.56)	0.020
Wave	<i>1</i>	Ref	Ref	Ref	Ref
	<i>2</i>	0.90 (0.46-1.78)	0.773	1.66 (0.38-7.27)	0.464
	<i>3</i>	1.66 (0.96-2.87)	0.072	1.95 (0.46-8.18)	0.318
	<i>4</i>	1.40 (0.78-2.53)	0.263	1.50 (0.35-6.38)	0.530
Vaccination status	<i>Non-vaccinated</i>	Ref	Ref	-	-
	<i>Vaccinated</i>	0.71 (0.32-1.57)	0.395	-	-
RT-PCR test result	<i>Negative</i>	Ref	Ref	-	-
	<i>Positive</i>	1.46	0.118	-	-
Time since onset	<i>Days</i>	1.00 (0.99-1.01)	0.778	-	-
<b>Clinical information at admission</b>					
Admission status	<i>Mild - moderate</i>	Ref	Ref	-	-
	<i>Severe - critical</i>	9.15 (1.28-65.33)	0.028	-	-
O2 saturation	<i>%</i>	0.98 (0.97-0.99)	<0.001	-	-
O2 flow	<i>&lt;5L</i>	Ref	Ref	Ref	Ref
	<i>5-10L</i>	2.05 (1.29-3.24)	0.002	2.52 (1.32-4.79)	0.005
	<i>&gt;10L</i>	4.73 (2.97-7.55)	6.79E-11	5.19 (2.62-10.29)	<0.001
<b>Laboratory results</b>					
WBC	<i>(10<sup>3</sup>/μl)</i>	1.00 (1.00-1.00)	0.031	-	-
Lymphocytes	$\geq 500(10^3/\mu l)$	Ref	Ref	Ref	Ref
	$< 500 (10^3/\mu l)$	1.88 (0.97-3.64)	0.0628	1.64 (0.98-2.74)	0.059
Haemoglobin	$\geq 12 \text{ g/dl}$	Ref	Ref	Ref	Ref
	$< 12 \text{ g/dl}$	2.09 (1.26-3.48)	0.004	2.55 (1.27-5.12)	0.010
<b>Time-dependent covariates</b>					
O2 Saturation	$\geq 94\%$	Ref	Ref	Ref	Ref
	$< 94\%$	2.10 (1.47-3.01)	<0.001	2.08 (1.14-3.81)	0.017
Systolic BP	<i>mmHg</i>	0.99 (0.98-1.00)	0.012	-	-
Diastolic BP	<i>mmHg</i>	0.98 (0.97-1.00)	0.034	-	-

337 **Abbreviations:** CI: Confidence interval; HR: Hazard ratio

338

339

## 340 Discussion

341 Although COVID-19 is a novel disease that emerged only in late 2019, it has attracted a great amount of  
342 scientific attention, likely due to its rapid evolution into a global pandemic, leading to a cumulative death  
343 toll of over 6.3 million people worldwide(as of July 2022), not including additional mortality from other  
344 causes due to the secondary effects of the pandemic on health services.<sup>1</sup> The evolution of the pandemic in  
345 LMIC was of particular concern due to the fragility and limited capacity of health systems and populations  
346 that are often subject to high prevalence of co-morbidities. However, the scientific literature on COVID-19  
347 in LMIC in general remains sparse. For Afghanistan in particular, among other factors, this is most likely  
348 related to challenges in data collection and reporting, the persistent limitations in availability of testing and  
349 in access to health care services for a large part of the population. The recent political changes and  
350 subsequent retreat or downscale of programs of many humanitarian organizations probably also had an  
351 impact on the quality of the pandemic documentation. MSF has been present throughout the pandemic and  
352 maintained a triage service for suspect cases consistently even between waves and a multidisciplinary  
353 inpatient CTC service throughout each of the first four waves, this study offers a unique insight into the  
354 clinical presentation of COVID-19 in the context of Afghanistan.

355 Our analysis focuses on the description of the clinical characteristics, severity, and outcomes of hospitalized  
356 COVID-19 patients in Herat, Afghanistan. A total of 1113 patients were included in this study with a  
357 median age of 60 years (IQR: 47-70 years) and a slightly higher proportion of females, which is comparable  
358 with other cohorts throughout the globe, even though an inverse gender distribution is more common  
359 elsewhere.<sup>13, 41-46</sup>

360 The proportion of patients classified as severe or critical at admission increased from 46 to 100% over the  
361 course of the four waves. This is explained by the limited bed capacity and resulting variation in rigor in  
362 the application of the admission criteria.

363 The distribution of symptoms within our cohort was similar to that of other cohorts with the most common  
364 symptoms at presentation including cough, shortness of breath, fever, headache, and chest pain.<sup>13, 42, 45-48</sup> Of

365 note is the gradual change in the proportion of patients presenting with fever, which decreased from 82%  
366 during the first wave to 24% during the fourth wave, in line with other contexts.<sup>49</sup> One large multicenter  
367 retrospective analysis on 21,461 unvaccinated Spanish COVID patients for example found that while fever  
368 was reported by 70-74% of patients during waves 1 and 2, this number decreased to 58.3% in successive  
369 waves.<sup>50</sup> One possible explanation is the emergence of new variants of the virus over time. Infection with  
370 the Omicron variant for example has also been shown to cause fever less frequently than the original virus  
371 strain.<sup>51, 52</sup>

372 Our analysis revealed many pathologically high blood pressure values, suggesting a high prevalence of  
373 untreated non-communicable diseases within the population. This may reflect difficulties in accessing care  
374 and receiving treatment for chronic diseases and may have had implications on adverse outcomes.

375 We compare complications and outcomes of our cohort to those of cohorts in similar settings. Our choice  
376 for comparison includes studies from Yemen, Libya, Sudan, and Somalia, other conflict affected LMICs  
377 with similarly fragile health systems.

378 Of our 1113 included hospitalized patients, a total of 78 (7%) experienced complications, with respiratory  
379 complications such as ARDS (3.3%) and respiratory failure (1.8%) being the most common. This number  
380 is comparatively low when regarding similar cohorts.<sup>43, 53</sup> As an example, one retrospective study including  
381 811 hospitalized patients in Libya reported that respiratory distress syndrome occurred in 14.3% of recorded  
382 patients.<sup>43</sup> Such differences in complication rates and adverse outcomes between settings are likely  
383 multifactorial, however vaccination status, access to confirmatory testing, oxygen therapy for hypoxaemic  
384 patients, prompt administration of steroids for patients requiring oxygen, close nursing monitoring, prone  
385 positioning physiotherapy techniques, adequate management of co-morbidities and coexisting pathologies,  
386 are all clinical aspects which are likely to vary significantly between settings and health care facilities and  
387 will have an impact on patient disease course.

388 Our outcome description relies on adverse outcome defined as transfer to a level 3 ICU or death. Though  
389 little to no data is available on the further development of transferred patients, anecdotal evidence

390 obtained from discussions with the physicians in charge states that a large proportion of patients died after  
391 transfer, so that our outcome approximates the mortality rate of the CTC. We do not have enough  
392 information to be able to attribute this high mortality among transferred patients to either their extreme  
393 severity, the resources available at the transfer destination or to other factors.

394 As a result, and because of variations in bed capacity and admission criteria, comparison of our outcomes  
395 with mortality rates from other studies should be interpreted with care. A total of 165 (14.8%) patients  
396 experienced an adverse outcome, which is low compared to similar cohorts. While the Libyan study  
397 found a mortality rate of 12.3%, other studies for example in Yemen, Somalia and Sudan described  
398 mortality rates of 35, 22 and 21% respectively.<sup>43, 48, 53, 54</sup> Another survival analysis performed on 131  
399 patients hospitalized in the main hospital in Mogadishu even documented a mortality rate of 40%.<sup>55</sup>

400 The proportion of adverse outcomes in our study population is low even in comparison with studies from  
401 high income countries. One large-scale multicenter observational study including almost half a million  
402 hospitalized COVID-19 patients from 49 different countries for example, showed a mortality of 20%.<sup>45</sup> A  
403 further multicenter observational study conducted in the United Kingdom with over 20.000 hospitalized  
404 COVID-19 patients, documented a mortality rate of 32%.<sup>46</sup>

405 Regarding predictive factors for an unfavorable outcome, we identified gender, higher age, O2 flow at  
406 admission, lymphopenia, anemia and an O2 saturation of under 94% as variables associated with adverse  
407 outcome. This is in line with the current literature.<sup>18-22, 24, 56, 57</sup> In our univariate analysis we also identified  
408 admission status and elevated WBC as factors associated with an adverse outcome. These were not  
409 included in the multivariate analysis due to strong correlation with other variables.

410 The proportion of vaccinated individuals in our cohort was low, with a total of 52 vaccinated patients,  
411 corresponding to 17% of patients admitted after vaccination started. This is in line with the current  
412 vaccination coverage in Afghanistan. As of July 2022, approximately 13% of the population were fully  
413 vaccinated (two doses when required for a specific type of vaccine).<sup>1</sup> Previous studies have identified supply  
414 shortage, insufficient cold chain infrastructure, geographical barriers, political instability and vaccine

415 hesitancy among the population caused by mistrust toward the government and lack of health education as  
416 causes of low vaccination coverage in Afghanistan.<sup>58-61</sup>

417 Self-reported COVID-19 vaccination status was not found to be significantly associated with a better  
418 outcome but given the low sample size the power of analysis for this indicator is expected to be very low  
419 and should thus be interpreted with caution.

#### 420 *Strengths and limitations*

421 The unique context of our study location differentiates us from other settings. For the past 40 years  
422 Afghanistan has been in almost permanent conflict of fluctuating intensity. The collapsing economy,  
423 displacement of approximately four million civilians and further political turmoil acutely seen since  
424 July/August 2021 have deteriorated an already struggling healthcare infrastructure, which suffers from a  
425 lack of emergency care services, equipment, medication and personnel.<sup>58</sup> There are currently estimated to  
426 be only 1.9 physicians per 10 000 people in the country.<sup>35</sup> The current pandemic was anticipated to further  
427 deteriorate the health care system.<sup>35</sup>

428 Despite the urgent need for evidence on the evolution of the pandemic to help evaluate and prioritize the  
429 most pressing challenges, reliable data is sparse and national data that is recorded is difficult to analyze  
430 given lack of completeness, lacking geographical coverage and lack of contextual information limiting  
431 interpretability. The national COVID-19 surveillance system suffers from wide-spread under-reporting and  
432 a lack of resources for laboratory confirmation and sequencing. In addition, many COVID-19 related deaths  
433 are thought to have occurred in the community, not captured by mortality surveillance.<sup>34</sup> A survey  
434 performed in 2020 didn't provide any insights into COVID-19 related mortality.<sup>62</sup> In this difficult context,  
435 our study provides insights into the in-hospital rate of adverse outcomes and the risk factors associated with  
436 severe COVID-19 in MSF's patient cohort in Herat. It is, however, to be noted that the resources available  
437 at an MSF-led facility are more important, specifically in terms of human resources as well as supply of  
438 essential drugs and biomedical equipment including oxygen therapy devices, which we infer has likely

439 decreased the rate of adverse outcomes when compared to local hospitals lacking funds, resources, and  
440 international support.

441 Another strength of our analysis lies in the large cohort of over 1000 patients, which ensures adequate  
442 statistical power. Furthermore, the use of a database with a web-interface provided capacity for real-time  
443 data entry, facilitating access to and real-time monitoring of essential patient indicators and thus allowing  
444 not only medico-operational monitoring but also regular remote quality checks by the co-investigators at  
445 Epicentre. In addition to regular exchange between the medical personnel at the study site and the  
446 investigators this allowed for continuous monitoring and high data reliability.

447 An important limitation is data completeness. Data collection was performed in a patient treatment setting  
448 from clinical files, and in times of high patient load it was common for physicians to skip variables that  
449 were not seen to be of immediate clinical relevance. Some of our variables, such as comorbidities, were  
450 collected at two time points, at admission and at discharge. Inconsistencies revealed weaknesses during  
451 data collection. Thus, several particularly incomplete or inconsistent variables were excluded from our  
452 analysis. Although case definitions for severity of disease was generally well understood in this project, the  
453 fast evolution of the disease in certain patients made a differentiation between severe and critical states  
454 challenging (e.g., for patients who required a gradual increase of O2 flow during the admission).

455 The proportion of patients who developed adverse outcome was the highest during the third wave, June to  
456 August 2021. This overlaps with the time of closure of Shaidayee hospital, the only other CTC in Herat,  
457 and equipped with mechanical ventilators. This led to the admission of critically ill patients to the MSF  
458 CTC who would otherwise have been referred to Shaidayee. Furthermore, during this time Afghanistan  
459 experienced a period of seasonal malnutrition, disruptive political changes and an escalation of conflict,  
460 which influenced supply chains.<sup>63</sup> In addition, it is likely the time when the delta variant of SARS-CoV-2  
461 circulated in Afghanistan. Given these and other similar variations and the fact that during peak times bed  
462 capacity was reached, it is likely that not only the effective admission criteria but also the case management  
463 capacity and available clinical resources per patient varied through time, meaning that 1) our results may



464 not be representative of complication and mortality rates that would have occurred in a setting not subject  
465 to these stressors and 2) complication and adverse outcome rates may not be comparable over time.

466 Though sequencing of the virus was only very rarely performed in Afghanistan, and not available within  
467 this project, SARS-CoV-2 variants of concern also spread through Afghanistan and likely lead to an  
468 evolution in severity patterns and immune escape. Extensive literature search identified one study focused  
469 on sequencing of SARS-CoV-2 in Afghanistan. In this study, the analysis of 122 COVID samples from  
470 foreign soldiers which were collected between February and May 2021 resulted in the detection of 20 virus  
471 strains belonging to the delta variant.<sup>64</sup> In June, news articles quoting the ministry of health, spoke of delta  
472 causing up to 60% of cases.<sup>65, 66</sup> Given the proximity and important population fluxes with Iran and the  
473 peak of Delta cases that is documented there in June 2021<sup>67, 68</sup>, one may conclude that the peak in case  
474 severity observed at the CTC during the 3<sup>rd</sup> wave was also related to this variant. Since the proportion of  
475 cases of each wave caused by the different variants is not known it is however not possible to conclude on  
476 the quantitative impact the variants had on severity.

477 As an MSF led hospital the CTC benefited from more resources and consequently better staffing,  
478 incorporating extended multi-disciplinary teams providing a coordinated holistic patient care approach  
479 including, but not limited to, intensive/critical care doctor and nurse supervision & mentoring of local staff,  
480 systematic physiotherapy for all inpatients, psychosocial supports and adequate nutrition in addition to  
481 advanced biomedical equipment, quality drugs and training, in contrast to what would usually be expected  
482 in a similar context. Concurrently, according to the patient flows established in Herat during most of the  
483 study period, many critical patients were admitted to Shaidayee hospital and not treated at the MSF CTC.  
484 These two factors mean that the rate of adverse outcome and rates of complications measured in our study  
485 are not necessarily representative of the context.

486 A further limitation of our analysis is that laboratory confirmation was not possible for all patients due to  
487 limited capacity. Many patients were thus diagnosed based on clinical criteria and epidemiological context,  
488 and sometimes RDTs. This was the case in particular in earlier waves where access to testing was even

489 scarcer. A separate analysis of all serologically confirmed cases was not conducted due to risk of bias, given  
490 that more severe cases were more likely to be lab tested.

#### 491 *Implications*

492 This study was initiated as a tool to aid the management of COVID-19 patients by MSF staff in different  
493 sites by giving real-time access to detailed clinical patient data during a time when treatment guidelines for  
494 COVID-19 patients evolved continuously and protocols applicable in resource limited settings needed to  
495 be developed from scratch. Automatized aggregated reports that were shared with COVID-19 referents and  
496 the local team helped to highlight weak spots almost in real-time, so that improvements could be  
497 continuously implemented.

498 Furthermore, given that in several countries the COVID-19 pandemic led to MSF implementing a level 2  
499 ICU for the first time, an additional aim of this comprehensive database was to evaluate the infrastructural  
500 quality of care and provide lessons learned to guide future emergency response interventions.

501 Our analysis could contribute to the creation of a risk score for severe disease outcomes to be considered  
502 for further outbreaks. The variables included in our analysis are all easily accessible and inexpensive, so  
503 adapted to a context with limited resources.

504 Overall, this study is among the few that longitudinally describe hospitalized COVID-19 patients, their risk  
505 factors, complications, and outcomes in a severely conflict affected LMIC setting. Despite the inherent  
506 limitations arising from scarce resources, a complex and quickly changing environment, and challenges  
507 related to the representativeness of our cohort of patients, our results show that indicators associated with  
508 adverse outcome of COVID-19 in Afghanistan are similar to those found in other settings.

509

510

511

512 **Author contributions**

513 MB, EP and FF designed the study. FF implemented and oversaw the data collection and performed  
514 regular quality control and follow-up. AK, MB, EP and FF performed the analysis. HH, SS, BM, GM,  
515 AA, AHT, BB, NP and MAZK provided . AK and FF wrote the first draft. All authors contributed to the  
516 final version.

517 **Acknowledgements**

518 This study was funded by MSF. The study protocol is based on a generic protocol developed by Helena Huerga,  
519 Sarala Nicholas, Mathieu Bastard, Maria Lightowler, Jeanne Haidar and Elisabeth Poulet at Epicentre. The authors  
520 would like to thank all involved health care and data administration staff in Afghanistan for their great work and  
521 dedication.

522

## 523 **References**

- 524 1. Organization WH. WHO Coronavirus (COVID-19) Dashboard,  
525 <https://covid19.who.int/region/emro/country/af> (accessed 18.07.2022 2022).
- 526 2. Wu Z and McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019  
527 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control  
528 and Prevention. *JAMA* 2020; 323: 1239-1242. 2020/02/25. DOI: 10.1001/jama.2020.2648.
- 529 3. Organization WH. Living guidance for clinical management of COVID-19,  
530 <https://apps.who.int/iris/bitstream/handle/10665/349321/WHO-2019-nCoV-clinical-2021.2-eng.pdf> (2021, accessed  
531 10.08.2022 2022).
- 532 4. Barks P and Finger F. Covidestim. Epicentre, GitHub, 2020.
- 533 5. da Rosa Mesquita R, Francelino Silva Junior LC, Santos Santana FM, et al. Clinical manifestations of  
534 COVID-19 in the general population: systematic review. *Wien Klin Wochenschr* 2021; 133: 377-382. 2020/11/27.  
535 DOI: 10.1007/s00508-020-01760-4.
- 536 6. Alimohamadi Y, Sepandi M, Taghdir M, et al. Determine the most common clinical symptoms in COVID-  
537 19 patients: a systematic review and meta-analysis. *J Prev Med Hyg* 2020; 61: E304-E312. 2020/11/06. DOI:  
538 10.15167/2421-4248/jpmh2020.61.3.1530.
- 539 7. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2  
540 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020; 8: 475-  
541 481. 2020/02/28. DOI: 10.1016/S2213-2600(20)30079-5.
- 542 8. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in  
543 patients with novel coronavirus pneumonia. *J Thromb Haemost* 2020; 18: 844-847. 2020/02/20. DOI:  
544 10.1111/jth.14768.
- 545 9. Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in  
546 Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. *Am J Gastroenterol* 2020; 115: 766-773.  
547 2020/04/15. DOI: 10.14309/ajg.0000000000000620.
- 548 10. AbuRuz S, Al-Azayzih A, ZainAlAbdin S, et al. Clinical characteristics and risk factors for mortality  
549 among COVID-19 hospitalized patients in UAE: Does ethnic origin have an impact. *PLoS One* 2022; 17: e0264547.  
550 2022/03/03. DOI: 10.1371/journal.pone.0264547.

- 551 11. Pya Y, Bekbossynova M, Gaipov A, et al. Mortality predictors of hospitalized patients with COVID-19:  
552 Retrospective cohort study from Nur-Sultan, Kazakhstan. *PLoS One* 2021; 16: e0261272. 2021/12/23. DOI:  
553 10.1371/journal.pone.0261272.
- 554 12. Garcia-Vidal C, Cozar-Llisto A, Meira F, et al. Trends in mortality of hospitalised COVID-19 patients: A  
555 single centre observational cohort study from Spain. *Lancet Reg Health Eur* 2021; 3: 100041. 2021/04/20. DOI:  
556 10.1016/j.lanep.2021.100041.
- 557 13. Myers LC, Parodi SM, Escobar GJ, et al. Characteristics of Hospitalized Adults With COVID-19 in an  
558 Integrated Health Care System in California. *JAMA* 2020; 323: 2195-2198. 2020/04/25. DOI:  
559 10.1001/jama.2020.7202.
- 560 14. Salluh JIF, Burghi G and Haniffa R. Intensive care for COVID-19 in low- and middle-income countries:  
561 research opportunities and challenges. *Intensive Care Med* 2021; 47: 226-229. 2020/11/14. DOI: 10.1007/s00134-  
562 020-06285-y.
- 563 15. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19  
564 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395: 1054-1062. 2020/03/15. DOI: 10.1016/S0140-  
565 6736(20)30566-3.
- 566 16. Macedo A, Goncalves N and Febrá C. COVID-19 fatality rates in hospitalized patients: systematic review  
567 and meta-analysis. *Ann Epidemiol* 2021; 57: 14-21. 2021/03/05. DOI: 10.1016/j.annepidem.2021.02.012.
- 568 17. Dessie ZG and Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-  
569 analysis of 42 studies and 423,117 patients. *BMC Infect Dis* 2021; 21: 855. 2021/08/23. DOI: 10.1186/s12879-021-  
570 06536-3.
- 571 18. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among  
572 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ* 2020; 369: m1966.  
573 2020/05/24. DOI: 10.1136/bmj.m1966.
- 574 19. Xie J, Covassin N, Fan Z, et al. Association Between Hypoxemia and Mortality in Patients With COVID-  
575 19. *Mayo Clin Proc* 2020; 95: 1138-1147. 2020/05/08. DOI: 10.1016/j.mayocp.2020.04.006.
- 576 20. Chatterjee NA, Jensen PN, Harris AW, et al. Admission respiratory status predicts mortality in COVID-19.  
577 *Influenza Other Respir Viruses* 2021; 15: 569-572. 2021/05/25. DOI: 10.1111/irv.12869.

- 578 21. Mejia F, Medina C, Cornejo E, et al. Oxygen saturation as a predictor of mortality in hospitalized adult  
579 patients with COVID-19 in a public hospital in Lima, Peru. *PLoS One* 2020; 15: e0244171. 2020/12/29. DOI:  
580 10.1371/journal.pone.0244171.
- 581 22. Altschul DJ, Unda SR, Benton J, et al. A novel severity score to predict inpatient mortality in COVID-19  
582 patients. *Sci Rep* 2020; 10: 16726. 2020/10/09. DOI: 10.1038/s41598-020-73962-9.
- 583 23. Marcos M, Belhassen-Garcia M, Sanchez-Puente A, et al. Development of a severity of disease score and  
584 classification model by machine learning for hospitalized COVID-19 patients. *PLoS One* 2021; 16: e0240200.  
585 2021/04/22. DOI: 10.1371/journal.pone.0240200.
- 586 24. Anai M, Akaike K, Iwagoe H, et al. Decrease in hemoglobin level predicts increased risk for severe  
587 respiratory failure in COVID-19 patients with pneumonia. *Respir Investig* 2021; 59: 187-193. 2020/12/08. DOI:  
588 10.1016/j.resinv.2020.10.009.
- 589 25. Zhang J, Wang X, Jia X, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-  
590 19 patients in Wuhan, China. *Clin Microbiol Infect* 2020; 26: 767-772. 2020/04/19. DOI:  
591 10.1016/j.cmi.2020.04.012.
- 592 26. Pyramid P. Population Pyramids of the World from 1950 to 2100,  
593 <https://www.populationpyramid.net/world/2019/> (2019, accessed 10.08.2022 2022).
- 594 27. Ritchie H and Roser M. Age structure, <https://ourworldindata.org/age-structure> (2019, accessed 10.08.2022  
595 2022).
- 596 28. Favas C, Jarrett P, Ratnayake R, et al. Country differences in transmissibility, age distribution and case-  
597 fatality of SARS-CoV-2: a global ecological analysis. *Int J Infect Dis* 2022; 114: 210-218. 2021/11/09. DOI:  
598 10.1016/j.ijid.2021.11.004.
- 599 29. Federation ID. IDF Diabetes Atlas, <https://diabetesatlas.org/atlas/tenth-edition/> (2021, accessed 10.08.2022  
600 2022).
- 601 30. Organization WH. Noncommunicable diseases, [https://www.who.int/news-room/fact-  
602 sheets/detail/noncommunicable-diseases](https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases) (2021, accessed 10.08.2022 2022).
- 603 31. Thienemann F, Ntusi NAB, Bategay E, et al. Multimorbidity and cardiovascular disease: a perspective on  
604 low- and middle-income countries. *Cardiovasc Diagn Ther* 2020; 10: 376-385. 2020/05/19. DOI:  
605 10.21037/cdt.2019.09.09.

- 606 32. Prabhakaran D, Anand S, Watkins DA, et al. Cardiovascular, Respiratory, and Related Disorders: Key  
607 Messages and Essential Interventions to Address Their Burden in Low- and Middle-Income Countries. In: rd,  
608 Prabhakaran D, Anand S, et al. (eds) *Cardiovascular, Respiratory, and Related Disorders*. Washington (DC), 2017.
- 609 33. Mousavi SH, Shah J, Giang HTN, et al. The first COVID-19 case in Afghanistan acquired from Iran.  
610 *Lancet Infect Dis* 2020; 20: 657-658. 2020/03/28. DOI: 10.1016/S1473-3099(20)30231-0.
- 611 34. Nemat A and Asady A. The Third Wave of the COVID-19 in Afghanistan: An Update on Challenges and  
612 Recommendations. *J Multidiscip Healthc* 2021; 14: 2043-2045. 2021/08/12. DOI: 10.2147/JMDH.S325696.
- 613 35. Shah J, Karimzadeh S, Al-Ahdal TMA, et al. COVID-19: the current situation in Afghanistan. *Lancet Glob*  
614 *Health* 2020; 8: e771-e772. 2020/04/06. DOI: 10.1016/S2214-109X(20)30124-8.
- 615 36. Cousins S. Afghanistan braced for second wave of COVID-19. *Lancet* 2020; 396: 1716-1717. 2020/11/30.  
616 DOI: 10.1016/S0140-6736(20)32529-0.
- 617 37. Asady A, Sediqi MF and Habibi SS. The Fourth Wave of the COVID-19 in Afghanistan: The Way  
618 Forward. *Infect Drug Resist* 2022; 15: 3369-3371. 2022/07/06. DOI: 10.2147/IDR.S365868.
- 619 38. Authority NSaI. Estimated Population of Afghanistan 2021-22,  
620 [https://web.archive.org/web/20210624204559/https://www.nsia.gov.af:8080/wp-content/uploads/2021/06/Estimated-](https://web.archive.org/web/20210624204559/https://www.nsia.gov.af:8080/wp-content/uploads/2021/06/Estimated-Population-of-Afghanistan1-1400.pdf)  
621 [Population-of-Afghanistan1-1400.pdf](https://web.archive.org/web/20210624204559/https://www.nsia.gov.af:8080/wp-content/uploads/2021/06/Estimated-Population-of-Afghanistan1-1400.pdf) (2021).
- 622 39. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of  
623 software platform partners. *J Biomed Inform* 2019; 95: 103208. 2019/05/13. DOI: 10.1016/j.jbi.2019.103208.
- 624 40. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven  
625 methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;  
626 42: 377-381. 2008/10/22. DOI: 10.1016/j.jbi.2008.08.010.
- 627 41. Rosenthal N, Cao Z, Gundrum J, et al. Risk Factors Associated With In-Hospital Mortality in a US  
628 National Sample of Patients With COVID-19. *JAMA Netw Open* 2020; 3: e2029058. 2020/12/11. DOI:  
629 10.1001/jamanetworkopen.2020.29058.
- 630 42. Wang Z, Ye D, Wang M, et al. Clinical Features of COVID-19 Patients with Different Outcomes in  
631 Wuhan: A Retrospective Observational Study. *Biomed Res Int* 2020; 2020: 2138387. 2020/10/09. DOI:  
632 10.1155/2020/2138387.

- 633 43. Elhadi M, Momen AA, Alsoufi A, et al. Epidemiological and clinical presentations of hospitalized COVID-  
634 19 patients in Libya: An initial report from Africa. *Travel Med Infect Dis* 2021; 42: 102064. 2021/04/21. DOI:  
635 10.1016/j.tmaid.2021.102064.
- 636 44. Di Fusco M, Shea KM, Lin J, et al. Health outcomes and economic burden of hospitalized COVID-19  
637 patients in the United States. *J Med Econ* 2021; 24: 308-317. 2021/02/09. DOI: 10.1080/13696998.2021.1886109.
- 638 45. Kartsonaki C. Characteristics and outcomes of an international cohort of 400,000 hospitalised patients with  
639 Covid-19. *medRxiv* 2021: 2021.2009.2011.21263419. DOI: 10.1101/2021.09.11.21263419.
- 640 46. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19  
641 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* 2020; 369:  
642 m1985. DOI: 10.1136/bmj.m1985.
- 643 47. Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. *J Med Virol*  
644 2020; 92: 1902-1914. 2020/04/16. DOI: 10.1002/jmv.25884.
- 645 48. Hasabo EA, Ayyad FA, Alam Eldeen SAM, et al. Clinical manifestations, complications, and outcomes of  
646 patients with COVID-19 in Sudan: a multicenter observational study. *Trop Med Health* 2021; 49: 91. 2021/11/16.  
647 DOI: 10.1186/s41182-021-00382-4.
- 648 49. Ben-Tov A, Lotan R, Gazit S, et al. Dynamics in COVID-19 symptoms during different waves of the  
649 pandemic among children infected with SARS-CoV-2 in the ambulatory setting. *Eur J Pediatr* 2022 2022/07/02.  
650 DOI: 10.1007/s00431-022-04531-7.
- 651 50. Ramos-Rincon JM, Cobos-Palacios L, Lopez-Sampalo A, et al. Differences in clinical features and  
652 mortality in very old unvaccinated patients ( $\geq 80$  years) hospitalized with COVID-19 during the first and  
653 successive waves from the multicenter SEMI-COVID-19 Registry (Spain). *BMC Geriatr* 2022; 22: 546. 2022/07/01.  
654 DOI: 10.1186/s12877-022-03191-4.
- 655 51. Petersen MS, S IK, Eliassen EH, et al. Clinical characteristics of the Omicron variant - results from a  
656 Nationwide Symptoms Survey in the Faroe Islands. *Int J Infect Dis* 2022; 122: 636-643. 2022/07/11. DOI:  
657 10.1016/j.ijid.2022.07.005.
- 658 52. Vihta KD, Pouwels KB, Peto TE, et al. Omicron-associated changes in SARS-CoV-2 symptoms in the  
659 United Kingdom. *Clin Infect Dis* 2022 2022/08/03. DOI: 10.1093/cid/ciac613.



- 660 53. Ahmed MAM, Hussein AM, Abdullahi AAM, et al. Cardiovascular risk factors and clinical outcomes of  
661 patients hospitalized with COVID-19 pneumonia in Somalia. *Ther Adv Infect Dis* 2022; 9: 20499361221095731.  
662 2022/05/03. DOI: 10.1177/20499361221095731.
- 663 54. Al-Waleedi AA, Naiene JD, Thabet AAK, et al. The first 2 months of the SARS-CoV-2 epidemic in  
664 Yemen: Analysis of the surveillance data. *PLoS One* 2020; 15: e0241260. 2020/10/30. DOI:  
665 10.1371/journal.pone.0241260.
- 666 55. Ali MM, Malik MR, Ahmed AY, et al. Survival analysis of all critically ill patients with COVID-19  
667 admitted to the main hospital in Mogadishu, Somalia, 30 March-12 June 2020: which interventions are proving  
668 effective in fragile states? *Int J Infect Dis* 2022; 114: 202-209. 2021/11/16. DOI: 10.1016/j.ijid.2021.11.018.
- 669 56. Niu J, Sareli C, Mayer D, et al. Lymphopenia as a Predictor for Adverse Clinical Outcomes in Hospitalized  
670 Patients with COVID-19: A Single Center Retrospective Study of 4485 Cases. *J Clin Med* 2022; 11 2022/02/16.  
671 DOI: 10.3390/jcm11030700.
- 672 57. Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and  
673 predictive study. *Signal Transduct Target Ther* 2020; 5: 33. 2020/04/17. DOI: 10.1038/s41392-020-0148-4.
- 674 58. Essar MY, Hasan MM, Islam Z, et al. COVID-19 and multiple crises in Afghanistan: an urgent battle.  
675 *Confl Health* 2021; 15: 70. 2021/09/19. DOI: 10.1186/s13031-021-00406-0.
- 676 59. Essar MY, Wara UU, Mohan A, et al. Challenges of COVID-19 vaccination in Afghanistan: A rising  
677 concern. *Ethics Med Public Health* 2021; 19: 100703. 2021/07/08. DOI: 10.1016/j.jemep.2021.100703.
- 678 60. Shoib S, Saleem SM, Essar MY, et al. Challenges faced by healthcare workers in Afghanistan amidst the  
679 COVID-19 pandemic and political instability: A call for action. *Clin Epidemiol Glob Health* 2022; 15: 101050.  
680 2022/05/03. DOI: 10.1016/j.cegh.2022.101050.
- 681 61. Nemat A, Bahez A, Salih M, et al. Public Willingness and Hesitancy to Take the COVID-19 Vaccine in  
682 Afghanistan. *Am J Trop Med Hyg* 2021; 105: 713-717. 2021/07/09. DOI: 10.4269/ajtmh.21-0231.
- 683 62. Saeedzai SA, Sahak MN, Arifi F, et al. COVID-19 morbidity in Afghanistan: a nationwide, population-  
684 based seroepidemiological study. *BMJ Open* 2022; 12: e060739. DOI: 10.1136/bmjopen-2021-060739.
- 685 63. Taconet A. Caring for patients with covid-19 in Afghanistan-another hard winter. *BMJ* 2022; 376: o175.  
686 2022/01/23. DOI: 10.1136/bmj.o175.

- 687 64. Maljkovic Berry I, Hang J, Fung C, et al. Genomic surveillance of SARS-CoV-2 in US military compounds  
688 in Afghanistan reveals multiple introductions and outbreaks of Alpha and Delta variants. *BMC Genomics* 2022; 23:  
689 513. 2022/07/16. DOI: 10.1186/s12864-022-08757-5.
- 690 65. Delta Variant Makes 50% of COVID-19 Infections in Afghanistan. *TOLOnews*, 27.06.2021 2021.
- 691 66. News A. COVID-19 Delta variant of COVID-19 spreading rapidly through Afghanistan. *ATN News*,  
692 26.09.2021 2021.
- 693 67. Sheikhi F, Yousefian N, Tehranipoor P, et al. Estimation of the basic reproduction number of Alpha and  
694 Delta variants of COVID-19 pandemic in Iran. *PLoS One* 2022; 17: e0265489. 2022/05/18. DOI:  
695 10.1371/journal.pone.0265489.
- 696 68. Yavarian J, Nejati A, Salimi V, et al. Whole genome sequencing of SARS-CoV2 strains circulating in Iran  
697 during five waves of pandemic. *PLoS One* 2022; 17: e0267847. 2022/05/03. DOI: 10.1371/journal.pone.0267847.

## 698 Supplement

### Supplementary Table 1:

Data collected at admission,  
discharge and during the  
patient's stay.


	Admission	Discharge	During stay
<b>Patient demographics</b>	X	-	-
<b>Comorbidities</b>	X	X	-
<b>Symptoms</b>	X	X	-
<b>Clinical examination</b>	X	-	-
<b>Recent medication</b>	X	-	-
<b>COVID-19 vaccination status</b>	X	-	-
<b>Oxygen therapy</b>	X	X	X <sup>1</sup>
<b>Supportive medication</b>	X	X	-
<b>Laboratory analyses</b>	(X)*	(X)*	(X)*
<b>Vital signs</b>	X	(X)*	X <sup>2</sup>
<b>COVID-19 testing</b>	(X)*	-	(X)*
<b>Supplementary diagnostics</b>	(X)*	-	-
<b>Complications</b>	-	X	-
<b>Outcome</b>	-	X	-

699 <sup>1</sup>As part of vital sign collection


700 <sup>2</sup>vital signs are collected multiple times daily, but only two values per day are entered into the database

701 \* Upon physicians' discretion and availability


702




Figure



Figure

**A**

medRxiv preprint doi: <https://doi.org/10.1101/2023.02.15.23285976>; this version posted February 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**B****C**